Evidence-based Interventions Programme List 3 will include 17 new interventions in England


Jan 2022

On January 20, 2022, the Academy of Medical Royal Colleges (AoMRC) launched a consultation on the latest set of guidance (List 3) of the Evidence-based Interventions (EBI) Programme. The deadline for comments submission is March 31, 2022.

EBI Programme is a joint enterprise between the AoMRC, NHS Clinical Commissioners, the National Institute for Health and Care Excellence (NICE) as well as NHS England and Improvement.

EBI program develops guidance sets (Lists) for tests, treatments, and procedures based on recommendations from the Expert Advisory Committee and NICE assessments. The guidance is aimed to support clinicians in improving patient outcomes and commissioners in developing their policies. List 1 (17 interventions) was published in 2018, List 2 (31 interventions) in 2020.

The guidelines provide clear, evidence-based criteria for consideration about the use of each intervention. The implementation of this proposed guidance would result in a reduction in unwarranted variation across England by standardizing the criteria.

Proposed List 3 covers 17 interventions across a range of medical specialties.

Breast Surgery:

  • Male gynecomastia reduction surgery;
  • Breast prosthesis removal;
  • Corrective surgery for congenital breast.

Cardiology: Angioplasty for PCI (percutaneous coronary intervention) in stable angina.

Endocrinology: Thyroid nodule referral and investigation.


  • Asymptomatic carotid artery stenosis screening;
  • Management of Abdominal Aortic Aneurysms (AAAs).

Gastrointestinal Surgery: Referral for bariatric surgery.


  • Optical coherence tomography (OCT) use in diabetic retinopathy referral;
  • Shared decision-making for cataract surgery;
  • Glaucoma referral criteria.


  • Non-visible haematuria;
  • Needle biopsy of the prostate;
  • Penile circumcision.

Plastic Surgery:

  • Abdominoplasty or Apronectomy;
  • Liposuction;
  • Diastasis recti repair.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news


Jun 2023

In May 2023, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries), two new Diagnostic Guidance (MRI fusion biopsy systems for diagnosing prostate cancer, automated ankle-brachial pressure index measurement devices to detect peripheral arterial disease), and three new Health Technology Evaluations (Digitally enabled therapies for adults with anxiety disorders / with depression, and point-of-care tests for urinary tract infections). Also, four clinical guidelines were updated.

Read more


Jun 2023

In May 2023, NICE announced that the Medtech innovation briefing (MIB) program was discontinued. MIBs were a part of the advice program at NICE commissioned by NHS England in 2014 to support the 5-Year Forward View and accelerate innovations. NICE will now focus on introducing new approaches to evaluating the most promising health technologies.

Read more


May 2023

On May 17, 2023, NHS England issued an updated version of the National Genomic Test Directory for cancer, which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Two new codes (test-indication combinations) were introduced.

Read more


May 2023

On April 28, 2023, the NHS Cancer Programme awarded £12.1 million to six innovations that improve the early detection and diagnosis of cancer. Awarded medical devices, in-vitro diagnostics, and digital health solutions are used to diagnose bowel, skin, liver, breast, ovarian, and esophageal cancer. They have proven their efficacy and clinical effectiveness and will be funded over the next 18 months to support rollout and real-world testing.

Read more


May 2023

In March 2023, Health Technology Wales published an Evidence Appraisal Report (EAR) and Guidance on photobiomodulation for the prevention and treatment of oral mucositis. Furthermore, seven Medtech-related Topic Exploration Reports (TER) were published, including single-pulse transcranial magnetic stimulation and AI-assisted ultrasound for deep vein thrombosis; however, Health Technology Wales will proceed with a full appraisal on one topic only - digital wound management tools.

Read more